Lighthouse Lab Services

A favorable reimbursement rate does not always make a payer contract profitable. If that payer also generates frequent denials, lengthy appeals, delayed payments, or a heavy administrative workload, the true value of the relationship may look very different from what appears on the fee schedule. Next Wednesday, Aug. 19, at noon EDT, Lighthouse's Ann Lambrix will join Gene Oberst of Quadax to explore how laboratories can evaluate the full financial and operational impact of payer performance. During this webinar, we’ll discuss how leading laboratories are using real-world analytics and reimbursement expertise to: ✅ Identify hidden costs within payer relationships ✅ Evaluate performance beyond contracted rates ✅ Uncover denial, payment, and variance trends If your laboratory is negotiating contracts, managing persistent reimbursement challenges, or looking for clearer insight into payer performance, this session will provide a more complete framework for determining which relationships are truly delivering value. Register here: https://lnkd.in/gKwRw5Eq

The real purpose of a mock inspection isn't to prove your laboratory is ready. It's to find where it isn't. A good mock inspection should uncover problems like: 🔹 An SOP that no longer reflects what happens at the bench. 🔹 Competency documentation that looked complete until someone examined it closely. 🔹 The quality process everyone assumes is working because it hasn't caused a problem yet. More importantly, mock inspections provide an opportunity to look beyond individual deficiencies and evaluate whether your laboratory's quality systems are actually working as intended. Inspection readiness shouldn't be a scramble that begins a few weeks before a survey. It should be the result of a laboratory that operates with compliance and quality built into its everyday processes. That's where an experienced outside perspective can be especially valuable. Lighthouse Lab Services provides on-site mock inspections to help laboratories prepare for CLIA, COLA, and CAP surveys. Our team identifies potential gaps, provides detailed recommendations and plans of correction, and can support laboratories before an initial or accreditation inspection as well as with corrective action following a survey. And because our expertise extends beyond inspection preparation into quality management, regulatory compliance, laboratory operations, staffing, physician oversight, and other areas of laboratory performance, we can help organizations address findings in the context of the broader operation. When was the last time your laboratory looked at its operation through an inspector's eyes?

Multi-Cancer Early Detection testing could create one of the most significant new patient care and revenue opportunities laboratories have seen in years. With a Medicare coverage pathway now established for qualifying FDA-authorized tests beginning as early as 2028, interested laboratories should be considering their MCED strategy. Join Jonathan Cohen of 20/20 BioLabs, Dr. Mao Mao of SeekIn, and Lighthouse Founder Jon Harol at 12 p.m. EDT, Sept. 2, for a forward-thinking discussion on: • The potential impact of MCED testing on cancer screening • The size and timing of the laboratory opportunity • Possible testing, validation and referral strategies • What laboratory leaders can begin doing now to prepare The market is still taking shape. Now is the right time to develop your organization's plan. Register below to attend the live event and receive a recording ⬇️

Two laboratories can use the same instruments, employ similarly trained scientists, and perform nearly identical assays while still operating as fundamentally different businesses. In our latest article, Lighthouse Founder Jon Harol explores the regulatory and economic divide between research and clinical diagnostics and why organizations capable of bridging that divide will help shape the future of laboratory medicine. Check out the full thought leadership piece below ⬇️ And don't forget, if your organization is working to move an assay from research into clinical use, Lighthouse Lab Services can help bridge the regulatory, operational, and commercial gaps.

The proposed 2027 Medicare Physician Fee Schedule is the latest signal that the financial pressure facing pathology practices is not relaxing. CAP projects that pathology reimbursement would decline about 2.4% overall next year. For CPT 88305 (the highest-volume surgical pathology service) CMS has proposed a 4% reduction to the global rate, including a 5% cut to the technical component and a 2% cut to the professional component. CMS is also requesting public comment on whether the 88305 surgical pathology code family may be misvalued, introducing the possibility of further scrutiny in 2027 or future rulemaking. At high volumes, small percentage cuts are not insignificant. They affect a group’s ability to invest in staffing, technology, turnaround times, new service lines, and long-term growth. To combat these reductions, pathology groups and laboratories need clear visibility into reimbursement by payer and code, underpayments and contract variance, denial trends, appeals performance, operating costs, and the true profitability of each service line. Lighthouse Lab Services is uniquely positioned to help pathology organizations connect those financial insights to the broader operation. Our integrated team brings together pathology-focused revenue cycle consulting, payer and contract analysis, billing audits, denial and appeal strategy, operational optimization, recruiting, and physician services. This breadth helps groups identify where revenue is being lost, strengthen performance, and make better-informed decisions about their future. Comments on the proposed 2027 fee schedule are due September 14. But pathology groups shouldn't to wait for the final rule to understand their revenue exposure and begin preparing. If your organization is modeling the potential impact or already experiencing sustained reimbursement pressure, our team can help evaluate the risks and build a more financially sustainable path forward.

Launching a laboratory to support wellness testing is easier than building one that lasts. As more wellness clinics bring diagnostic testing in-house or expand existing laboratory services, the strategic opportunity is clear: better patient experiences, greater control over testing, and new revenue streams. While it may seem straightforward, many organizations discover that operating a laboratory requires far more than selecting the right tests. Quality management, CLIA compliance, staffing, workflow design, physician oversight, reimbursement strategy, instrumentation, and operational scalability all become critical as testing volumes increase. Without the right foundation, rapid growth can quickly introduce inefficiencies, compliance risks, and costly setbacks. At Lighthouse Lab Services, we partner with wellness platforms at every stage of the laboratory lifecycle, from concept through commercialization. Our integrated team helps wellness providers build, operate, optimize, and grow laboratory programs that are designed for long-term success, bringing together expertise in regulatory compliance, laboratory operations, physician services, staffing, commercialization, and revenue strategy. The most successful wellness laboratories aren't just growing. They're building an operational foundation that can support the next stage of that growth.

Not all payer contracts deliver the value they promise. While reimbursement rates often drive contracting decisions, they don't tell the full story. Denials, appeals, payment delays, contract variance, and administrative burden all impact your laboratory's bottom line. Join Quadax and Lighthouse Lab Services at noon EDT, Wednesday, August 19, as we combine real-world analytics with reimbursement strategy to show how leading laboratories are evaluating payer performance, uncovering hidden costs, and using data to make smarter operational and contracting decisions. At Lighthouse, our RCM Team helps laboratories look beyond reimbursement rates to build financially sustainable payer strategies. From contract analysis and reimbursement optimization to denial management, appeals, revenue cycle consulting, and commercialization planning, our integrated team helps laboratories maximize revenue while supporting long-term growth. Register using the link below to learn how a more strategic approach to payer performance can strengthen both your revenue cycle and your laboratory's future. https://lnkd.in/gKwRw5Eq

We're excited to have Ann Lambrix, Executive Director of RCM Consulting, speaking at the Association for Diagnostics & Laboratory Medicine Clinical Lab Expo next week! Reimbursement Strategy, Scientific Session 📍 Anaheim Convention Center | Room 210CD 📅 Monday, July 27 | 2:30–4:00 PM Ann will cover: • Reimbursement mechanics and payer model structures • Revenue management strategies • Cost vs. opportunity analysis across workflow models • Building financially sustainable laboratory programs At Lighthouse Lab Services, we believe reimbursement shouldn't be viewed as an isolated billing function. It's one part of a much larger strategy that includes regulatory planning, laboratory operations, payer contracting, commercialization, and sustainable growth. By bringing these disciplines together, we help laboratories optimize and grow high-performing laboratories. If you'll be attending ADLM, stop by Ann's session or connect with her during the conference. Whether you're evaluating your reimbursement strategy, navigating payer challenges, or exploring new testing opportunities, she'd be happy to continue the conversation.

Significant changes have been proposed for New York State Laboratory Director qualifications. Here's what you need to know: New York's Public Health and Health Planning Council has approved proposed revisions that would replace Part 19 with new Subpart 58-6 governing Clinical Laboratory Director qualifications. While the new framework is not yet formally in effect and final adoption is still pending, laboratories should begin preparing for what comes next. 🔹CLEP has temporarily suspended acceptance of new initial Certificate of Qualification (CQ) applications, as well as amendment applications. Initial CQ applications received before June 24, 2026, will continue to be processed while the new application system is finalized. 🔹The proposed framework creates separate Certificate of Qualification pathways for Laboratory Directors and Technical Directors. Depending on an individual's responsibilities, some professionals may need to obtain both certificates and pay separate application fees. 🔹Once the new process is implemented, individuals seeking to serve as a Laboratory Director will be required to submit a new Laboratory Director CQ application and pay the applicable fee. 🔹Current certificate holders should pay close attention to their renewal timelines. Those with certificates expiring between July and September 2026 who have already submitted renewals under the current process will need to reapply using the new application format, while individuals with later expiration dates will transition at renewal if they meet the updated eligibility requirements. Most importantly, laboratories should begin evaluating leadership qualifications now. Under the proposed regulations, individuals who do not meet the new Laboratory Director eligibility requirements would not be able to obtain a Laboratory Director Certificate of Qualification, meaning affected laboratories may need to appoint a qualified replacement by January 2027. Lighthouse Lab Services will continue monitoring the rulemaking process and share additional updates as final guidance becomes available. In the meantime, feel free to follow up with us directly for any questions or if you need assistance recruiting a qualified director to meet these requirements.

Join us tomorrow, July 22, at 2 p.m. EDT, for an important discussion on one of the most closely watched laboratory compliance cases in recent years. Lighthouse Lab Services will host Matthew Rutledge, President of MD Labs, and Danielle Tangorre, Partner at Robinson+Cole and lead counsel in the litigation, for a practical discussion of the landmark MD Labs qui tam case and what laboratory leaders should take away from it. Whether you're a laboratory owner, executive, medical director, compliance professional, or revenue cycle leader, you'll gain practical insight into how this case may influence laboratory operations and compliance strategies moving forward. Can't attend live? Register anyway, and we'll send you the webinar recording after the event. https://lnkd.in/gHdT2ntA